VERO BEACH, Fla., March 1, 2025 /PRNewswire/ -- QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid ® (sacrosidase) Oral Solution has been shown to be 81% ...
Austin, TX – December 29, 2011 – Stratfor, the leading publisher of global intelligence and analysis, today announced that CSID™, the leading provider of global, enterprise-level identity protection ...
Sucraid is an oral enzyme replacement therapy of the genetically determined sucrase deficiency. The Food and Drug Administration (FDA) has approved Sucraid ® (sacrosidase) Oral Solution single-use ...
AUSTIN, Texas--(BUSINESS WIRE)--CSID, the global leader in identity protection today announced the acquisition of Dataspaces Corporation Limited. Based in London, England, Dataspaces will augment CSID ...
AUSTIN, Texas--(BUSINESS WIRE)--The State of South Carolina today announced that CSID, the leading provider of global, enterprise-level identity protection and fraud detection technologies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results